Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Centrinone (LCR-263) 是 polo 样激酶 4 的可逆抑制剂,对PLK4的Ki 值为0.16 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 435 | 现货 | ||
2 mg | ¥ 792 | 现货 | ||
5 mg | ¥ 1,197 | 现货 | ||
10 mg | ¥ 1,997 | 现货 | ||
50 mg | ¥ 4,490 | 现货 | ||
100 mg | ¥ 6,410 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,694 | 现货 |
产品描述 | Centrinone (LCR-263) (LCR-263) is a reversible inhibitor of polo-like kinase 4 (PLK4; Ki:0.16 nM). |
靶点活性 | Aurora A:171 nM (ki), Aurora B:436.76 nM (ki), PLK4 (G95L):68.57 nM (ki), PLK4:0.16 nM (ki) |
体外活性 | Centrinone (LCR-263) treatment causes centrosome depletion in human and other vertebrate cells and it treatment reduces centriole number in multiciliated Xenopus epithelial cells, which indicates that Plk4 also controls centriole amplification in differentiated cells. Centrinone (LCR-263) treatment of HeLa human cervical carcinoma cells leads to a progressive reduction in foci containing centriolar and pericentriolar material markers at each round of cell division, until most cells lack centrioles and centrosomes. Centrosome loss irreversibly arrests normal cells in a senescence-like G1 state by a p53-dependent mechanism that is independent of DNA damage, stress, Hippo signaling, extends mitotic duration, or segregation errors[1]. |
别名 | LCR-263 |
化合物与蛋白结合的复合物 |
Crystal Structure of Plk4 Kinase Domain Bound to Centrinone |
分子量 | 633.65 |
分子式 | C26H25F2N7O6S2 |
CAS No. | 1798871-30-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 31 mg/mL (48.92 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.5782 mL | 7.8908 mL | 15.7816 mL | 39.454 mL |
5 mM | 0.3156 mL | 1.5782 mL | 3.1563 mL | 7.8908 mL | |
10 mM | 0.1578 mL | 0.7891 mL | 1.5782 mL | 3.9454 mL | |
20 mM | 0.0789 mL | 0.3945 mL | 0.7891 mL | 1.9727 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Centrinone 1798871-30-3 Cell Cycle/Checkpoint Chromatin/Epigenetic PLK Aurora Kinase LCR 263 Polo-like Kinase (PLK) LCR263 Inhibitor inhibit LCR-263 inhibitor